The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier； methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition； and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
